Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.

Yamashita K, Hatae R, Hiwatashi A, Togao O, Kikuchi K, Momosaka D, Yamashita Y, Kuga D, Hata N, Yoshimoto K, Suzuki SO, Iwaki T, Iihara K, Honda H.

Diagn Interv Imaging. 2019 Jul - Aug;100(7-8):411-419. doi: 10.1016/j.diii.2019.02.010. Epub 2019 Apr 1.

PMID:
30948344
2.

Endoscopic Endonasal Approach Combined with a Simultaneous Transcranial Approach for Giant Pituitary Tumors.

Kuga D, Toda M, Ozawa H, Ogawa K, Yoshida K.

World Neurosurg. 2019 Jan;121:173-179. doi: 10.1016/j.wneu.2018.10.047. Epub 2018 Oct 16.

PMID:
30336293
3.

Treatment Strategy for Tuberculum Sellae Meningiomas Based on a Preoperative Radiological Assessment.

Kuga D, Toda M, Yoshida K.

World Neurosurg. 2018 Dec;120:e1279-e1288. doi: 10.1016/j.wneu.2018.09.054. Epub 2018 Sep 19.

PMID:
30240863
4.

An elderly case of malignant small cell glioma with hemorrhage coexistent with a calcified pilocytic astrocytoma component in the cerebellar hemisphere.

Sangatsuda Y, Hata N, Suzuki SO, Akagi Y, Hatae R, Kuga D, Yoshimoto K, Momosaki S, Iwaki T, Iihara K.

Neuropathology. 2018 Oct;38(5):493-497. doi: 10.1111/neup.12478. Epub 2018 May 31.

PMID:
29851180
5.

Pediatric ganglioglioma with an H3 K27M mutation arising from the cervical spinal cord.

Okuda T, Hata N, Suzuki SO, Yoshimoto K, Arimura K, Amemiya T, Akagi Y, Kuga D, Oba U, Koga Y, Ohga S, Iwaki T, Iihara K.

Neuropathology. 2018 Apr 19. doi: 10.1111/neup.12471. [Epub ahead of print]

PMID:
29675936
6.

Use of Anti-phospho-girdin Antibodies to Visualize Intestinal Tuft Cells in Free-Floating Mouse Jejunum Cryosections.

Mizutani Y, Kuga D, Iida M, Ushida K, Takagi T, Tokita Y, Takahashi M, Asai M.

J Vis Exp. 2018 Mar 21;(133). doi: 10.3791/57475.

7.

Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification.

Akagi Y, Yoshimoto K, Hata N, Kuga D, Hatae R, Amemiya T, Sangatsuda Y, Suzuki SO, Iwaki T, Mizoguchi M, Iihara K.

Brain Tumor Pathol. 2018 Apr;35(2):81-89. doi: 10.1007/s10014-018-0313-4. Epub 2018 Mar 22.

PMID:
29569163
8.

The Effectiveness of Salvage Treatments for Recurrent Lesions of Oligodendrogliomas Previously Treated with Upfront Chemotherapy.

Kuga D, Hata N, Akagi Y, Amemiya T, Sangatsuda Y, Hatae R, Yoshimoto K, Mizoguchi M, Iihara K.

World Neurosurg. 2018 Jun;114:e735-e742. doi: 10.1016/j.wneu.2018.03.069. Epub 2018 Mar 16.

PMID:
29551724
9.

Measurement of the perfusion fraction in brain tumors with intravoxel incoherent motion MR imaging: validation with histopathological vascular density in meningiomas.

Togao O, Hiwatashi A, Yamashita K, Kikuchi K, Momosaka D, Yoshimoto K, Kuga D, Mizoguchi M, Suzuki SO, Iwaki T, Van Cauteren M, Iihara K, Honda H.

Br J Radiol. 2018 May;91(1085):20170912. doi: 10.1259/bjr.20170912. Epub 2018 Feb 16.

10.

High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.

Yoshimoto K, Hatae R, Suzuki SO, Hata N, Kuga D, Akagi Y, Amemiya T, Sangatsuda Y, Mukae N, Mizoguchi M, Iwaki T, Iihara K.

Neuropathology. 2018 Feb;38(1):3-10. doi: 10.1111/neup.12408. Epub 2017 Aug 25.

PMID:
28840946
11.

Long-term survival after multidisciplinary therapy for residual gallbladder cancer with peritoneal dissemination: a case report.

Kuga D, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M.

Surg Case Rep. 2017 Dec;3(1):76. doi: 10.1186/s40792-017-0351-x. Epub 2017 Jun 14.

12.

Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.

Yoshimoto K, Hatae R, Sangatsuda Y, Suzuki SO, Hata N, Akagi Y, Kuga D, Hideki M, Yamashita K, Togao O, Hiwatashi A, Iwaki T, Mizoguchi M, Iihara K.

Brain Tumor Pathol. 2017 Jul;34(3):103-112. doi: 10.1007/s10014-017-0287-7. Epub 2017 Apr 26.

PMID:
28447171
13.

Tyrosine Phosphorylation of an Actin-Binding Protein Girdin Specifically Marks Tuft Cells in Human and Mouse Gut.

Kuga D, Ushida K, Mii S, Enomoto A, Asai N, Nagino M, Takahashi M, Asai M.

J Histochem Cytochem. 2017 Jun;65(6):347-366. doi: 10.1369/0022155417702586. Epub 2017 Apr 4.

14.

Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status.

Hata N, Yoshimoto K, Hatae R, Kuga D, Akagi Y, Sangatsuda Y, Suzuki SO, Shono T, Mizoguchi M, Iihara K.

Onco Targets Ther. 2017 Jan 18;10:429-437. doi: 10.2147/OTT.S125587. eCollection 2017.

15.

Insular primary glioblastomas with IDH mutations: Clinical and biological specificities.

Hata N, Hatae R, Yoshimoto K, Murata H, Kuga D, Akagi Y, Sangatsuda Y, Suzuki SO, Iwaki T, Mizoguchi M, Iihara K.

Neuropathology. 2017 Jun;37(3):200-206. doi: 10.1111/neup.12362. Epub 2017 Jan 24.

PMID:
28116838
16.

Deferred radiotherapy and upfront procarbazine-ACNU-vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade.

Hata N, Yoshimoto K, Hatae R, Kuga D, Akagi Y, Suzuki SO, Iwaki T, Shono T, Mizoguchi M, Iihara K.

Onco Targets Ther. 2016 Nov 17;9:7123-7131. eCollection 2016.

17.

A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology.

Hatae R, Hata N, Suzuki SO, Yoshimoto K, Kuga D, Murata H, Akagi Y, Sangatsuda Y, Iwaki T, Mizoguchi M, Iihara K.

Neuropathology. 2017 Jun;37(3):191-199. doi: 10.1111/neup.12347. Epub 2016 Oct 28.

PMID:
27792249
18.

Current Trends and Healthcare Resource Usage in the Hospital Treatment of Primary Malignant Brain Tumor in Japan: A National Survey Using the Diagnostic Procedure Combination Database (J-ASPECT Study-Brain Tumor).

Yoshimoto K, Kada A, Kuga D, Hatae R, Murata H, Akagi Y, Nishimura K, Kurogi R, Nishimura A, Hata N, Mizoguchi M, Sayama T, Iihara K.

Neurol Med Chir (Tokyo). 2016 Nov 15;56(11):664-673. Epub 2016 Sep 27.

19.

Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data.

Hatae R, Hata N, Yoshimoto K, Kuga D, Akagi Y, Murata H, Suzuki SO, Mizoguchi M, Iihara K.

PLoS One. 2016 Aug 16;11(8):e0160489. doi: 10.1371/journal.pone.0160489. eCollection 2016.

20.

Diagnostic utility of intravoxel incoherent motion mr imaging in differentiating primary central nervous system lymphoma from glioblastoma multiforme.

Yamashita K, Hiwatashi A, Togao O, Kikuchi K, Kitamura Y, Mizoguchi M, Yoshimoto K, Kuga D, Suzuki SO, Baba S, Isoda T, Iwaki T, Iihara K, Honda H.

J Magn Reson Imaging. 2016 Nov;44(5):1256-1261. doi: 10.1002/jmri.25261. Epub 2016 Apr 19.

PMID:
27093558
21.

Grading diffuse gliomas without intense contrast enhancement by amide proton transfer MR imaging: comparisons with diffusion- and perfusion-weighted imaging.

Togao O, Hiwatashi A, Yamashita K, Kikuchi K, Keupp J, Yoshimoto K, Kuga D, Yoneyama M, Suzuki SO, Iwaki T, Takahashi M, Iihara K, Honda H.

Eur Radiol. 2017 Feb;27(2):578-588. doi: 10.1007/s00330-016-4328-0. Epub 2016 Mar 22.

PMID:
27003139
22.

Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression.

Murata H, Yoshimoto K, Hatae R, Akagi Y, Mizoguchi M, Hata N, Kuga D, Nakamizo A, Amano T, Sayama T, Iihara K.

J Neurooncol. 2015 Oct;125(1):33-41. doi: 10.1007/s11060-015-1886-y. Epub 2015 Aug 14.

PMID:
26272600
23.

Girdin is phosphorylated on tyrosine 1798 when associated with structures required for migration.

Omori K, Asai M, Kuga D, Ushida K, Izuchi T, Mii S, Enomoto A, Asai N, Nagino M, Takahashi M.

Biochem Biophys Res Commun. 2015 Mar 20;458(4):934-40. doi: 10.1016/j.bbrc.2015.02.065. Epub 2015 Feb 20.

24.

Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma.

Qin Y, Fu M, Takahashi M, Iwanami A, Kuga D, Rao RG, Sudhakar D, Huang T, Kiyohara M, Torres K, Dillard C, Inagaki A, Kasahara N, Goodglick L, Braun J, Mischel PS, Gordon LK, Wadehra M.

J Biol Chem. 2014 May 16;289(20):13974-85. doi: 10.1074/jbc.M113.543728. Epub 2014 Mar 18.

25.

Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.

Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, Vandenberg SR, Zhou H, Marie SK, Mischel PS, Cavenee WK, Furnari FB.

Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14164-9. doi: 10.1073/pnas.1211962109. Epub 2012 Aug 13.

26.

Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma.

Ma X, Yoshimoto K, Guan Y, Hata N, Mizoguchi M, Sagata N, Murata H, Kuga D, Amano T, Nakamizo A, Sasaki T.

Neuro Oncol. 2012 Sep;14(9):1153-62. doi: 10.1093/neuonc/nos145. Epub 2012 Jul 27.

27.

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK.

Cancer Discov. 2012 May;2(5):458-71. doi: 10.1158/2159-8290.CD-11-0284. Epub 2012 Mar 31.

28.

An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.

Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS.

Cancer Discov. 2011 Oct;1(5):442-56. doi: 10.1158/2159-8290.CD-11-0102. Epub 2011 Sep 15. Erratum in: Cancer Discov. 2012 Feb;2(2):290-1.

29.

Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR.

Yoshimoto K, Ma X, Guan Y, Mizoguchi M, Nakamizo A, Amano T, Hata N, Kuga D, Sasaki T.

Brain Tumor Pathol. 2011 Oct;28(4):291-6. doi: 10.1007/s10014-011-0046-0. Epub 2011 Jun 21.

30.

Loss of heterozygosity analysis in malignant gliomas.

Mizoguchi M, Kuga D, Guan Y, Hata N, Nakamizo A, Yoshimoto K, Sasaki T.

Brain Tumor Pathol. 2011 Jul;28(3):191-6. doi: 10.1007/s10014-011-0038-0. Epub 2011 Jun 1. Review. Erratum in: Brain Tumor Pathol. 2011 Jul;28(3):197.

PMID:
21629980
31.

MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance.

Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, Araki Y, Kuga D, Nakamizo A, Amano T, Ma X, Hayashi K, Sasaki T.

Clin Cancer Res. 2010 Aug 15;16(16):4289-97. doi: 10.1158/1078-0432.CCR-10-0207. Epub 2010 Jul 2.

32.

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation.

Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, Rajasekaran A, Liau LM, Cloughesy TF, Dikic I, Brennan C, Wu H, Mischel PS, Perera T, Mellinghoff IK.

Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6459-64. doi: 10.1073/pnas.0911188107. Epub 2010 Mar 22.

33.

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.

Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS.

Sci Signal. 2009 Dec 15;2(101):ra82. doi: 10.1126/scisignal.2000446.

34.

Prevalence of copy-number neutral LOH in glioblastomas revealed by genomewide analysis of laser-microdissected tissues.

Kuga D, Mizoguchi M, Guan Y, Hata N, Yoshimoto K, Shono T, Suzuki SO, Kukita Y, Tahira T, Nagata S, Sasaki T, Hayashi K.

Neuro Oncol. 2008 Dec;10(6):995-1003. doi: 10.1215/15228517-2008-064. Epub 2008 Aug 12.

35.

Narrowing of the regions of allelic losses of chromosome 1p36 in meningioma tissues by an improved SSCP analysis.

Guan Y, Hata N, Kuga D, Yoshimoto K, Mizoguchi M, Shono T, Suzuki SO, Tahira T, Kukita Y, Higasa K, Yokoyama N, Nagata S, Iwaki T, Sasaki T, Hayashi K.

Int J Cancer. 2008 Apr 15;122(8):1820-6.

36.

[Neuroradiology of brain stem hemorrhage].

Kuga D, Sasaki T.

Nihon Rinsho. 2006 Nov 28;64 Suppl 8:455-9. Japanese. No abstract available.

PMID:
17469593
37.

Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity.

Uesaka T, Shono T, Kuga D, Suzuki SO, Niiro H, Miyamoto K, Matsumoto K, Mizoguchi M, Ohta M, Iwaki T, Sasaki T.

J Neurooncol. 2007 Sep;84(2):119-29. Epub 2007 Mar 15.

PMID:
17361331
38.

[Vertebral hemangioma extending into the spinal canal: case report].

Kuga D, Shono T, Miyazono M, Sasaki T.

No Shinkei Geka. 2004 Jan;32(1):43-7. Japanese.

PMID:
14978923
39.

Individual differences, perceived task characteristics, and preferences for teaching and coaching.

Chelladurai P, Kuga DJ, O'Bryant CP.

Res Q Exerc Sport. 1999 Jun;70(2):179-89.

PMID:
10380249

Supplemental Content

Support Center